Longitude Prize on ALS launches to advance AI-based drug discovery

The Longitude Prize on ALS, a new £7.5 million global challenge prize, has launched today to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral sclerosis), the most common form of MND (motor neurone disease).

ALS is a progressive neurodegenerative disease that damages the nerves in the brain and spinal cord.

Signals from the brain stop reaching muscles, leading to severe muscle degeneration.

Eventually this affects the muscles that are used to swallow food and drink, and those used to breathe.

Although some very limited treatments exist to slow the progression of the disease for a short time, the complexity of the disease means that there are no long-term treatments and no cure.

For the first time, however, advances in AI mean innovators now have the opportunity to outpace the disease by unlocking vast quantities of patient data that have been generated in the last decade.

Tris Dyson, Managing Director at Challenge Works who was diagnosed with ALS in 2023 said: “Never before have we had the power to unlock the complexity of MND, and in particular ALS, and accelerate along the road to long-term treatments, and, I hope one day, a cure.

“The Longitude Prize on ALS makes this possible, convening the largest data set of ALS patient data of its kind ever made available and rewarding researchers to use AI to identify the most promising drug targets.”

The Longitude Prize on ALS is principally funded by the MND Association and designed and delivered by Challenge Works, supported by Nesta.

Additional funders include Nesta, the Alan Davidson Foundation, My Name’5 Doddie Foundation, LifeArc, FightMND, The 10,000 Brains Project, Answer ALS and The Packard Center at Johns Hopkins.

Seeking innovators from across medical research, biotech, techbio, pharmaceuticals and AI, the Prize will initially reward 20 of the most promising entrants with ‘Discovery Awards’ of £100,000 each.

Teams will be judged on the potential for their approach to identify and validate drug targets driving understanding of the disease and supporting onward translation into drug discovery.

The entry window is open from today and remains open until 3 December 2025.

The 20 successful entrants will be named in the first half of 2026.

Lucy Hawking, journalist and daughter of the MND Association’s late Patron, Prof. Stephen Hawking said: “The Longitude Prize on ALS is an important step towards increasing our understanding of motor neurone disease, and specifically ALS.

“My father lived with MND for over 50 years, the longest known survivor with this condition and his great wish was that one day, a cure would be found. I’m proud to support the Longitude Prize and wish all entrants the very best.”

Tanya Curry, Chief Executive at the Motor Neurone Disease Association, added: “Empowering some of the brightest minds across science and technology to come together, the Longitude Prize on ALS will initiate transformative change for people living with motor neurone disease.

We are investing as a principal funder as enabling such collaborations, as well as the level of unprecedented data we’re working to unlock, marks the start of a significant milestone for drug discovery, the MND Association and wider MND community in how we understand and consequently tackle the disease.”

After the initial £100,000 ‘Discovery Awards’ have been awarded in 2026, ten teams will progress to a second stage, receiving a further £200,000 in 2027 to build the evidence base for their proposed therapeutic targets in silico and in the lab.

In 2028, five teams will then receive £500,000 to undertake validation of the highest potential identified targets in the wet lab.

The winning team will be announced in early 2031 and will be awarded £1 million for identifying the target with the strongest evidence of therapeutic potential.

The Longitude Prize on ALS is the third Longitude Prize run by Challenge Works to incentivise breakthrough solutions for some of the world’s most challenging issues.

It follows the success of the Longitude Prize on AMR that announced a winner in 2024, and the Longitude Prize on Dementia that will announce a winner in 2026.